Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 4;16(7):1070-1078.
doi: 10.1093/ecco-jcc/jjac010.

Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey

Pierre Ellul  1 , Joana Revés  2 , Bárbara Abreu  2 , María Chaparro  3 , Javier P Gisbert  3 , Mariangela Allocca  4   5 , Gionata Fiorino  4   5 , Brigida Barberio  4   5 , Fabiana Zingone  4   5 , Anthea Pisani  1 , David Cassar  1 , George Michalopoulos  6 , Gerassimos Mantzaris  7 , Ioannis Koutroubakis  8 , Konstantinos Karmiris  9 , Konstantinos Katsanos  10 , Dana Ďuricova  11   12 , Johan Burisch  13   14 , Gorm Roager Madsen  13   14 , Christian Maaser  15 , Arebi Naila  16 , Eleni Orfanoudaki  8 , Vladimir Milivojevic  17 , Anthony Buisson  18   19 , Luisa Avedano  20 , Salvo Leone  20 , Joana Torres  2   21
Affiliations

Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey

Pierre Ellul et al. J Crohns Colitis. .

Abstract

Introduction: Anti-SARS-CoV-2 vaccine clinical trials did not include patients with immune-mediated conditions such as inflammatory bowel disease [IBD]. We aimed to describe the implementation of anti-SARS-CoV-2 vaccination among IBD patients, patients' concerns, and the side effect profile of the anti-SARS-CoV-2 vaccines, using real-world data.

Methods: An anonymous web-based self-completed survey was distributed in 36 European countries between June and July 2021. The results of the patient characteristics, concerns, vaccination status, and side effect profile were analysed.

Results: In all 3272 IBD patients completed the survey, 79.6% had received at least one dose of anti-SARS-CoV-2 vaccine, and 71.7% had completed the vaccination process. Patients over 60 years old had a significantly higher rate of vaccination [p < 0.001]. Patients' main concerns before vaccination were the possibility of having worse vaccine-related adverse events due to their IBD [24.6%], an IBD flare after vaccination [21.1%], and reduced vaccine efficacy due to IBD or associated immunosuppression [17.6%]. After the first dose of the vaccine, 72.4% had local symptoms and 51.4% had systemic symptoms [five patients had non-specified thrombosis]. Adverse events were less frequent after the second dose of the vaccine and in older patients. Only a minority of the patients were hospitalised [0.3%], needed a consultation [3.6%], or had to change IBD therapy [13.4%] after anti-SARS-CoV-2 vaccination.

Conclusions: Although IBD patients raised concerns about the safety and efficacy of anti-SARS-CoV-2 vaccines, the implementation of vaccination in those responding to our survey was high and the adverse events were comparable to the general population, with minimal impact on their IBD.

Keywords: COVID-19; Inflammatory bowel disease; SARS-CoV-2; vaccination.

PubMed Disclaimer

Substances